Eli Lilly and Company $LLY Shares Sold by CENTRAL TRUST Co

CENTRAL TRUST Co lowered its position in Eli Lilly and Company (NYSE:LLY) by 0.9% during the third quarter, HoldingsChannel.com reports. The fund owned 41,713 shares of the company’s stock after selling 397 shares during the quarter. Eli Lilly and Company accounts for approximately 0.9% of CENTRAL TRUST Co’s holdings, making the stock its 28th largest holding. CENTRAL TRUST Co’s holdings in Eli Lilly and Company were worth $48,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also modified their holdings of the company. Artemis Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 4.9% in the 3rd quarter. Artemis Wealth Advisors LLC now owns 467 shares of the company’s stock worth $540,000 after buying an additional 22 shares in the last quarter. Endeavor Private Wealth Inc. grew its stake in Eli Lilly and Company by 9.1% in the 3rd quarter. Endeavor Private Wealth Inc. now owns 864 shares of the company’s stock valued at $999,000 after acquiring an additional 72 shares during the last quarter. King Luther Capital Management Corp increased its holdings in Eli Lilly and Company by 2.0% during the 3rd quarter. King Luther Capital Management Corp now owns 212,351 shares of the company’s stock valued at $245,707,000 after acquiring an additional 4,148 shares in the last quarter. Banyan Capital Management Inc. purchased a new position in Eli Lilly and Company during the 3rd quarter valued at about $868,000. Finally, Spectrum Planning & Advisory Services Inc. increased its holdings in Eli Lilly and Company by 127.2% during the 3rd quarter. Spectrum Planning & Advisory Services Inc. now owns 534 shares of the company’s stock valued at $618,000 after acquiring an additional 299 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. HSBC lifted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Argus increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Royal Bank Of Canada raised their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective for the company in a research report on Tuesday, September 15th. Finally, Leerink Partners lifted their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,416.64.

Recent Eli Lilly and Company Headlines

Here are a few of the latest headlines about LLY:

• Positive Sentiment: China approved orforglipron, making Lilly the first company with an approved GLP-1 weight-loss pill in the country. The approval gives LLY a route into a large obesity-treatment market and a potential edge while rival oral treatments await regulatory decisions. Reuters article
• Neutral Sentiment: Lilly’s obesity collaboration with Fauna Bio designated a second discovery target using AI-based research. It adds to the early-stage pipeline, but any commercial impact is uncertain and likely years away. Fauna Bio announcement
• Negative Sentiment: Potential U.S. drug-price negotiations could pressure Lilly revenue, according to recent reporting. This policy risk may weigh on expectations even as the company expands its obesity portfolio. Drug-pricing risk report

Eli Lilly and Company Stock Down 0.3%

LLY opened at $1,433.34 on Friday. The firm has a market cap of $1.35 trillion, a P/E ratio of 46.52, a PEG ratio of 1.72 and a beta of 0.40. The business’s fifty day simple moving average is $1,236.58 and its 200 day simple moving average is $1,108.27. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,460.00. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $7.02 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.